		Technical Data
A0855-91D	ACVRL1, CT (Serine/Threonine-protein Kinase Receptor R3, SKR3, Activin Receptor-like Kinase 1, ALK-1, TGF-B Superfamily Receptor Type I, TSR-I, ACVRLK1, ALK1)

Description:
ACVRL1 is a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. This protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2.

Applications:
Suitable for use in ELISA, Western Blot, and Immunohistochemistry. Other applications not tested.

Recommended Dilution:
ELISA: 1:1,000
Western Blot: 1:100-1:500
Immunohistochemistry: 1:50-1:100
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Type	Isotype	Clone	Grade
Pab	IgG		Affinity Purified

Size		Storage	Shipping	Source	Host
100ug		-20°C	Blue Ice	Human	Rabbit

Concentration:

~0.25mg/ml

Immunogen:

Synthetic peptide selected from the C-terminal region of human ACVRL1 (KLH).

Purity:

Purified by Protein G affinity chromatography.

Form

Supplied as a liquid in PBS, 0.09% sodium azide.

Specificity:

Recognizes human ACVRL1.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1.Strausberg, R.L., et al., Proc. Natl. Acad. Sci. USA 99(26):16899-16903 (2002). 2.Berg, J.N., et al., Am. J. Hum. Genet. 61(1):60-67 (1997). 3.Johnson, D.W., et al., Nat. Genet. 13(2):189-195 (1996). 4.ten Dijke, P., et al., Oncogene 8(10):2879-2887 (1993). 5.Attisano, L., et al., Cell 75(4):671-680 (1993).